Genomics’ Post

Recently cardiologists from Austria published a consensus statement on the diagnosis and management of Hypertrophic Cardiomyopathy (HCM). As the document states, " It is the aim of this Austrian consensus statement to aggregate the most important recommendations of international guidelines in the context of the Austrian healthcare system and resources. Austria is a high-income country with a healthcare system provided with high-level operational and human resources. Due to compulsory health insurance, more than 99% of the Austrian population have full and unrestricted access to all healthcare system services. All diagnostic methods and treatments for HCM including septal reduction therapy (SRT) are available at different tertiary care and HCM expert centers throughout Austria. Therefore, the recommendations issued in the following are applicable to all Austrian residents who are holders of a valid health insurance." As several of our members reside in Austria, we are very happy to see the development of such a clear document and approach based on the latest international guidelines - big thanks to everybody involved! We are very much open on working with specialists in Austria to improve patient healthcare and well-being. Nicolas Verheyen Nikolaos Bonaros Anna Rab Sebastian Reinstadler Daniel Scherr Gábor G. Tóth Thomas Weber Marc-Michael Zaruba Daniel Zimpfer Gerhard Pölzl #hypertrophic #cardiomyopathy #hcm #patient #Austria 👇 👇 👇 https://lnkd.in/dMR45Zvs

📢✅ [BIG NEWS] #METAglut1 our first IVD blood test to aid the diagnosis of Glut1 deficiency syndrome, obtained universal national coverage by French National Health Insurance as of February 22, 2024 by assurance maladie , the french national Health Insurance #Glut1DS or De Vivo Disease is a rare, still largely underdiagnosed #neurometabolic disorder leading to years of medical wandering and suffering for most patients 🙏Many thanks to all our partners for helping us to reach this step! Direction générale de l'offre de soins (DGOS)and Haute Autorité de Santé who granted us the Forfait Innovation, and for their trust in the clinical utility our technology is bringing. Greater Paris University Hospitals - AP-HP, and all the French hospitals involved, Institut de Génétique Moléculaire de Montpellier (IGMM), as well as CERBA HEALTHCARE who enabled us to make this test available in France. 👉 Find our Press Release here: https://lnkd.in/ecWbK-F8 #ivdttest #diagnostics #coverage #raredisease #ForfaitInnovation https://lnkd.in/ecWbK-F8

A topic that is becoming increasingly important in our lives: 𝚝𝚑𝚎 𝚊𝚍𝚟𝚊𝚗𝚌𝚎𝚖𝚎𝚗𝚝𝚜 𝚒𝚗 𝚖𝚎𝚍𝚒𝚌𝚊𝚕 𝚝𝚎𝚌𝚑𝚗𝚘𝚕𝚘𝚐𝚢, 𝚜𝚙𝚎𝚌𝚒𝚏𝚒𝚌𝚊𝚕𝚕𝚢 𝚙𝚛𝚎𝚌𝚒𝚜𝚒𝚘𝚗 𝚖𝚎𝚍𝚒𝚌𝚒𝚗𝚎, 𝚊𝚗𝚍 𝚒𝚝𝚜 𝚒𝚖𝚙𝚕𝚒𝚌𝚊𝚝𝚒𝚘𝚗𝚜 𝚘𝚗 𝚘𝚞𝚛 𝚏𝚒𝚗𝚊𝚗𝚌𝚒𝚊𝚕 𝚙𝚕𝚊𝚗𝚗𝚒𝚗𝚐.  This article delves into how precision medicine is revolutionising cancer treatments BUT at a steep cost. 🔍 Key Points: 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲: This innovative approach tailors treatments based on individual genetic profiles, significantly improving outcomes for cancer patients. 𝗥𝗶𝘀𝗶𝗻𝗴 𝗖𝗼𝘀𝘁𝘀: The sophistication of these treatments 𝘭𝘦𝘢𝘥𝘴 𝘵𝘰 𝘩𝘪𝘨𝘩𝘦𝘳 𝘤𝘰𝘴𝘵𝘴, which might not be fully covered by hospital plans 𝗜𝗺𝗽𝗮𝗰𝘁 𝗼𝗻 𝗜𝗻𝘀𝘂𝗿𝗮𝗻𝗰𝗲: With ongoing advancements in medical technology and treatments, the list of drugs covered under hospital plans is constantly evolving Why Should You Care?: Understanding the financial implications of these medical advancements is critical.  Hospital plans are indispensable, covering a significant portion of large medical bills. 𝙃𝙤𝙬𝙚𝙫𝙚𝙧, 𝙩𝙝𝙚𝙮 𝙤𝙛𝙩𝙚𝙣 𝙙𝙤 𝙣𝙤𝙩 𝙥𝙧𝙤𝙫𝙞𝙙𝙚 𝙥𝙖𝙮𝙤𝙪𝙩𝙨 𝙛𝙤𝙧 𝙞𝙣𝙘𝙤𝙢𝙚 𝙧𝙚𝙥𝙡𝙖𝙘𝙚𝙢𝙚𝙣𝙩 𝙙𝙪𝙧𝙞𝙣𝙜 𝙡𝙤𝙣𝙜-𝙩𝙚𝙧𝙢 𝙞𝙡𝙡𝙣𝙚𝙨𝙨𝙚𝙨, nor do they cover all new treatments. ⚠️ 𝐈𝐟 𝐲𝐨𝐮 𝐰𝐞𝐫𝐞 𝐮𝐧𝐚𝐛𝐥𝐞 𝐭𝐨 𝐰𝐨𝐫𝐤 𝐝𝐮𝐞 𝐭𝐨 𝐢𝐥𝐥𝐧𝐞𝐬𝐬, 𝐡𝐨𝐰 𝐰𝐨𝐮𝐥𝐝 𝐲𝐨𝐮 𝐦𝐚𝐧𝐚𝐠𝐞 𝐲𝐨𝐮𝐫 𝐝𝐚𝐲-𝐭𝐨-𝐝𝐚𝐲 𝐞𝐱𝐩𝐞𝐧𝐬𝐞𝐬 𝐚𝐧𝐝 𝐟𝐚𝐦𝐢𝐥𝐲 𝐜𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭𝐬? ⚠️ 𝐀𝐫𝐞 𝐲𝐨𝐮 𝐩𝐫𝐞𝐩𝐚𝐫𝐞𝐝 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐧𝐞𝐞𝐝𝐢𝐧𝐠 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐧𝐨𝐭 𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐛𝐲 𝐲𝐨𝐮𝐫 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐩𝐥𝐚𝐧? ✅ 𝗥𝗲𝘃𝗶𝗲𝘄 𝗬𝗼𝘂𝗿 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲: It's crucial to ensure your health insurance matches your potential needs, especially with the rapid advancements in medical treatments. ✅ 𝗜𝗻𝗰𝗹𝘂𝗱𝗲 𝗜𝗻𝗰𝗼𝗺𝗲 𝗣𝗿𝗼𝘁𝗲𝗰𝘁𝗶𝗼𝗻: Adding income replacement insurance can safeguard your financial health against the unpredictability of long-term illness. ✅ 𝗦𝘁𝗮𝘆 𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱: Keep updated with changes in your insurance policy and what it means for treatments like precision medicine. 𝐈𝐟 𝐲𝐨𝐮 𝐨𝐧𝐥𝐲 𝐡𝐚𝐯𝐞 𝐚 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐩𝐥𝐚𝐧 𝐚𝐧𝐝 𝐚𝐫𝐞 𝐜𝐨𝐧𝐜𝐞𝐫𝐧𝐞𝐝 𝐚𝐛𝐨𝐮𝐭 𝐠𝐚𝐩𝐬 𝐢𝐧 𝐲𝐨𝐮𝐫 𝐜𝐨𝐯𝐞𝐫𝐚𝐠𝐞, 𝐞𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐥𝐲 𝐟𝐨𝐫 𝐧𝐞𝐰 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐢𝐧𝐜𝐨𝐦𝐞 𝐫𝐞𝐩𝐥𝐚𝐜𝐞𝐦𝐞𝐧𝐭, 𝐈 𝐞𝐧𝐜𝐨𝐮𝐫𝐚𝐠𝐞 𝐲𝐨𝐮 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐨𝐮𝐭 📲 We can ensure your insurance strategy is comprehensive and tailored to meet both today’s needs and tomorrow’s challenges. https://lnkd.in/gZ-7aZZU

Cirrhosis.xyz, a concise and powerful one-word domain name,  it's easy to remember, type and brand, making it a valuable tool for any business looking to make a lasting impression in the digital landscape! Startups in the health and wellness industry, particularly those focused on liver health, medical research, or alcohol addiction treatment, could benefit from using this domain, with targeted marketing efforts, potentially justifying the higher value of mediation. Potential end users for Cirrhosis.xyz 1. Pharmaceutical companies:  Cirrhosis is a disease of the liver, so companies specializing in liver health products or drugs would be interested in this domain name to promote their offering. 2. Health service providers:  Hospitals, clinics, or medical centers that focus on liver disease may want to use this domain name to educate patients about cirrhosis, offer treatment options, or provide a source of support. 3. Health insurance companies:  Insurers may want to use this domain name to provide information about cirrhosis coverage, preventative measures, and lifestyle changes to reduce the risk of developing the disease. You can find it on DAN Good ESTIBOT estimate CHEERS https://lnkd.in/d-KGJg2q

likely not to be enough < Strengthening health care access and quality, including universal health insurance coverage, and health care systems in the prevention, early diagnosis, management, and treatment of cancer will be paramount for improving clinical outcomes and slowing projected trends>

So nice, tolles Paper meiner Kolleg*innen zur Nutzung von Integrativer Medizin "Use and acceptance of traditional, complementary and integrative medicine in Germany—an online representative cross-sectional study" Aus den results: "Among participants, 70% stated that they had used TCIM at some point in their lives, with 32% doing so in the last 12 months and 18% currently. The most common reason given (17%) was musculoskeletal pain. For their own health, 39% stated that TCIM is important. ... As a complementary treatment strategy to conventional medicine, 35% considered TCIM to be optimal (“Complementary Medicine”), 33% in combination with conventional medicine (“Integrative Medicine”) and 5% without conventional medicine (“Alternative Medicine”). The majority of the participants were in favor of more research on TCIM and stated that the costs of TCIM services should be covered by health insurance companies (71% and 69%, respectively)." https://lnkd.in/ez6tvH7y

Cancer remains a major health concern in the US, with millions of new cases diagnosed each year. But beyond the human cost, cancer care also carries a hefty financial burden. To ensure timely and accessible treatment, streamlining the authorization process is crucial. The Problem: Delays and Denials in Approvals Prior authorization (PA) and insurance approvals for cancer treatments often create significant roadblocks. These complex processes involve multiple parties and can lead to delays of weeks, impacting access to critical care. Studies show delays in essential services like imaging and chemotherapy, and some patients may even abandon treatment plans due to frustrations. For specific treatments like proton beam therapy, the initial denial rates can be as high as 60%, leading to additional months of waiting. These administrative hurdles significantly impact patient care. The Solution: AI to the Rescue Artificial intelligence (AI) offers a promising solution to expedite and improve PA processes. Companies like Health Care Service Corporation (HCSC) have seen a dramatic 1400x increase in processing speed through AI. Learn more: https://hubs.ly/Q02vCbN60

4 takeaways from AHIP 2024 Walgreens pitches payers; progress on value-based care; GLP-1s dominate the conversation and Marc Harrison's gene therapy call to action

Financial hurdles, including rising deductibles and out-of-pocket costs, affect patients with cancer disproportionately. Many are often forced to choose between necessary treatments and financial stability. In cancer care, value-based care allows for reduced out-of-pocket expenses for life-saving treatments like immunotherapy, ensuring that patients are not burdened by unnecessary financial strain for vital therapies. #VBC #ValueBasedCare #Healthcare

Are prior authorizations necessary for medical procedures? According to a recent opinion piece in the New York Times, some prior authorizations are unnecessary and can lead to a waste of money and delay care. While no medical director in their right mind would deny chemotherapy for Acute Lymphoblastic Leukemia, some prior authorization requests can be absurd, such as a request to biopsy toenail fungus. It's important to review prior authorization requests to ensure that only necessary diagnostic and therapies are approved. Check out the article below for more insights. Link to article: https://lnkd.in/eP4MB_99